LAS194046

LAS194046 is an investigational **inhaled pan-Janus kinase inhibitor** being developed by Almirall for inflammatory airway diseases. Preclinical and translational studies describe it as a **selective small-molecule pan-JAK inhibitor** designed for **topical lung delivery** with limited systemic exposure, with activity against allergen-driven airway inflammation, late asthmatic response, phospho-STAT signaling, and neutrophil inflammatory mediator release. Published work supports potential use in **asthma**, including severe non-T2 asthma, and **chronic obstructive pulmonary disease**, particularly where corticosteroid responsiveness is poor; combination experiments with fluticasone propionate showed synergistic anti-inflammatory effects in vitro.